Bhuvana Sagar, MD: Genetic testing, in lung cancer, that looks for mutations is a hot area of research at this time. We cover testing when the end result is tied to drug policy coverage. So, if the mutation requires broad-based next-generation sequence mutation testing, where multiple genetic tests are being done at the same time and the test results are not directly tied to a drug approval in that particular setting, we do not cover that testing. The reason is that there are several mutation studies that can be done. The quality of these need to be verified. Interpretation of those test results also has to be verified, and several providers, at this time, do not have a clear understanding of how to interpret those tests and tie them to treatment decisions. At this point in time, we don’t have enough evidence to support multiple genetic mutation studies where there’s no clear evidence of benefit in that particular tumor.
If a drug is approved along with companion diagnostic testing, we cover the companion diagnostic testing. And we typically cover the drug therapy when the test results or test mutation is positive. It is not a very complicated decision for us. When the FDA typically approves it, we generally cover it. At Cigna, we do not cover tests at this time just for clinical trial enrollments. We have looked at that approach, but we feel that, in general, our coverage policy has always been directed to cover tests and treatments that have enough clinical trial evidence to support [their] clinical utility or benefit in that particular setting. So, we do not cover tests where that clinical utility has not been clearly defined.
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
The Senate Finance Committee has introduced bipartisan legislation that proposes using Medicaid and Medicare programs to help prevent and reduce generic drug shortages; US indicators for COVID-19, flu, and respiratory syncytial virus (RSV) declined further last week; findings from a recent study reveal growing disparities in child death rates across racial and ethnic groups.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
What Mass General Brigham Is Doing to Combat Prostate Cancer Disparities Among Men of Color
May 5th 2024Quoc-Dien Trinh, MD, MBA, chief of urology at Brigham & Women's Faulkner Hospital, highlighted successful efforts to improve prostate cancer care access for underserved communities in Massachusetts.
Read More